MGC Pharmaceuticals Ltd. announced it has signed a distribution agreement with Anden Bio Naturals S.A, for the exclusive distribution and commercialisation of MGC Pharma phytocannabinoid-derived medicines in Peru and Bolivia for a term of five years (the `Agreement'). The Agreement helps to solidify MGC Pharma's footprint in Latin America, following the execution of its BrazilInvest joint venture agreement as announced on 22 November 2019 and the Brazil distribution agreement with Onix as announced on 19 June 2019. New distribution agreement signed with Anden, a Peruvian distributor, giving MGC Pharma access to their extensive network of pharmacies, private medical clinics and an oncological private insurance system. Anden is the first to legally import phytocannabinoid based medicines in Peru. Anden granted the right to exclusively distribute and commercialise MGC Pharma phytocannabinoid-derived medicines in Peru, and subsequently Bolivia, subject to conditions Strategic agreement for MGC Pharma, expanding its presence in the Latin American medicinal cannabis market with a well-established partner in the region. Anden will distribute MGC Pharma products through its distribution network, which includes the largest medicine distributors and retailers, as well as key players in the healthcare and insurance sectors. Consequently, MGC Pharma will be in a prime position for coverage by public and private insurance, including an oncological platform with over 1m affiliated patients. Relevant in-country approvals to commence import of MGC Products under the Agreement are expected to be obtained by Anden during first quarter of 2020. The company to develop and provide a white label line of nutraceutical products for Anden to commercialise, provided it does not compete with MGC Pharma products.